193 related articles for article (PubMed ID: 34558841)
1. Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis.
Gallucci GM; Trottier J; Hemme C; Assis DN; Boyer JL; Barbier O; Ghonem NS
Hepatol Commun; 2021 Dec; 5(12):2035-2051. PubMed ID: 34558841
[TBL] [Abstract][Full Text] [Related]
2. Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol.
Ghonem NS; Auclair AM; Hemme CL; Gallucci GM; de la Rosa Rodriguez R; Boyer JL; Assis DN
Clin Pharmacol Ther; 2020 Dec; 108(6):1213-1223. PubMed ID: 32480421
[TBL] [Abstract][Full Text] [Related]
3. Profiling serum bile acid glucuronides in humans: gender divergences, genetic determinants, and response to fenofibrate.
Trottier J; Perreault M; Rudkowska I; Levy C; Dallaire-Theroux A; Verreault M; Caron P; Staels B; Vohl MC; Straka RJ; Barbier O
Clin Pharmacol Ther; 2013 Oct; 94(4):533-43. PubMed ID: 23756370
[TBL] [Abstract][Full Text] [Related]
4. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
5. Fibrates and cholestasis.
Ghonem NS; Assis DN; Boyer JL
Hepatology; 2015 Aug; 62(2):635-43. PubMed ID: 25678132
[TBL] [Abstract][Full Text] [Related]
6. Effect of different doses of ursodeoxycholic acid in chronic liver disease.
Podda M; Ghezzi C; Battezzati PM; Bertolini E; Crosignani A; Petroni ML; Zuin M
Dig Dis Sci; 1989 Dec; 34(12 Suppl):59S-65S. PubMed ID: 2598769
[TBL] [Abstract][Full Text] [Related]
7. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.
Assis DN; Abdelghany O; Cai SY; Gossard AA; Eaton JE; Keach JC; Deng Y; Setchell KD; Ciarleglio M; Lindor KD; Boyer JL
J Clin Gastroenterol; 2017 Feb; 51(2):e11-e16. PubMed ID: 27428727
[TBL] [Abstract][Full Text] [Related]
8. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
Trauner M; Gulamhusein A; Hameed B; Caldwell S; Shiffman ML; Landis C; Eksteen B; Agarwal K; Muir A; Rushbrook S; Lu X; Xu J; Chuang JC; Billin AN; Li G; Chung C; Subramanian GM; Myers RP; Bowlus CL; Kowdley KV
Hepatology; 2019 Sep; 70(3):788-801. PubMed ID: 30661255
[TBL] [Abstract][Full Text] [Related]
9. Unique bile acid profiles in the bile ducts of patients with primary sclerosing cholangitis.
Kayashima A; Sujino T; Fukuhara S; Miyamoto K; Kubosawa Y; Ichikawa M; Kawasaki S; Takabayashi K; Iwasaki E; Kato M; Honda A; Kanai T; Nakamoto N
Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38780302
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
Dohmen K; Tanaka H; Haruno M
Fukuoka Igaku Zasshi; 2013 Oct; 104(10):350-61. PubMed ID: 24511666
[TBL] [Abstract][Full Text] [Related]
11. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of cholestatic liver disease].
Pleşa A
Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):733-6. PubMed ID: 14756010
[TBL] [Abstract][Full Text] [Related]
13. Novel and emerging therapies for cholestatic liver diseases.
Goldstein J; Levy C
Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
[TBL] [Abstract][Full Text] [Related]
14. Fenofibrate in primary sclerosing cholangitis; a randomized, double-blind, placebo-controlled trial.
Hatami B; Mosala M; Hassani AH; Ardakani MJE; Gholami S; Zali MR
Pharmacol Res Perspect; 2022 Aug; 10(4):e00984. PubMed ID: 35822553
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
Baghdasaryan A; Fuchs CD; Österreicher CH; Lemberger UJ; Halilbasic E; Påhlman I; Graffner H; Krones E; Fickert P; Wahlström A; Ståhlman M; Paumgartner G; Marschall HU; Trauner M
J Hepatol; 2016 Mar; 64(3):674-81. PubMed ID: 26529078
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
[TBL] [Abstract][Full Text] [Related]
17. Urinary Elimination of Bile Acid Glucuronides under Severe Cholestatic Situations: Contribution of Hepatic and Renal Glucuronidation Reactions.
Perreault M; Wunsch E; Białek A; Trottier J; Verreault M; Caron P; Poirier GG; Milkiewicz P; Barbier O
Can J Gastroenterol Hepatol; 2018; 2018():8096314. PubMed ID: 29850459
[TBL] [Abstract][Full Text] [Related]
18. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
Lemoinne S; Pares A; Reig A; Ben Belkacem K; Kemgang Fankem AD; Gaouar F; Poupon R; Housset C; Corpechot C; Chazouillères O
Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):521-528. PubMed ID: 30100231
[TBL] [Abstract][Full Text] [Related]
19. Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary Cholangitis.
Gallucci GM; Alsuwayt B; Auclair AM; Boyer JL; Assis DN; Ghonem NS
Inflammation; 2022 Dec; 45(6):2570-2581. PubMed ID: 35838934
[TBL] [Abstract][Full Text] [Related]
20. Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis.
Cai SY; Yu D; Soroka CJ; Wang J; Boyer JL
J Hepatol; 2021 Mar; 74(3):550-559. PubMed ID: 33039404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
